Differentiated approach to the implementation of preventive and anti-epidemic measures among military personnel based on the COVID-19 disease risk assessment scale

Abstract

Aim of the study - to develop a scale for assessing the risk of COVID-19 disease for a differentiated approach in conducting preventive and anti-epidemic measures among military personnel.

Material and methods. An array of published data was analyzed to select the risk factors for a possible COVID-19 disease. The disease risk assessment scale proposed on the basis of this analysis is implemented in the form of a table in MS Excel and a program in MS Visual Studio in C# with the inclusion of recommendations for making a management decision.

Results. The risk factors for COVID-19 disease were selected and included in the questionnaire. A scale for assessing the risk of COVID-19 disease was developed: when a risk factor was identified, one point was assigned; otherwise, zero points were assigned. Then all the points are added together, and this amount is considered proportional to the risk of contracting COVID-19. The resulting total score is correlated with the recommendations for the scope of preventive and anti-epidemic measures. With the program implementation of the scale, it is possible to quickly make an adequate management decision.

Conclusion. The use of such approaches can be a significant contribution to the fight against the new coronavirus infection.

Keywords:blood type, coronavirus infection, smoking, obesity, program implementation, risk factors, risk assessment scale

Funding. Authors declare no financial support.

Conflict of interest. The authors declare that there is no conflict of interest.

Contribution. Concept and design of the study - Kryukov E.V., Cherkashin D.V., Reutsky I.A.; collection and processing of the material - Sobolev A.D., Levankov B.V., Dmitriev M.V., Efimov S.V., Kutelev G.G.; writing of the text - Sobolev A.D., Efimov S.V., Solntsev V.N.; editing - Cherkashin D.V., Reutskiy I.A., Bucenko S.A.

For citation: Kryukov E.V., Cherkashin D.V., Reutskiy I.A., Solntsev V.N., Bucenko S.A., Sobolev A.D., Levankov B.V., Dmitriev M.V., Efimov S.V., Kutelev G.G. Differentiated approach to the implementation of preventive and anti-epidemic measures among military personnel based on the COVID-19 disease risk assessment scale. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2021; 10 (2): 31-8. DOI: https://doi.org/10.33029/2305-3496-2021-10-2-31-38 (in Russian)

References

1. Kutyrev V.V., Popova A.Yu., Smolensky V.Yu. et al. Epidemiological features of the novel coronavirus infection (COVID-19). Message 1: Models for the implementation of preventive and anti-epidemic measures. Prob-lemy osobo opasnykh infektsiy [Problems of Particularly Dangerous Infections]. 2020; (1): 6-13. (in Russian)

2. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020; 395 (10 223): 497506. DOI: DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

3. Malinnikova E.Yu. New coronavirus infection. Today’s look at the 21st century pandemic. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 [2 (33)]: 18-32. (in Russian)

4. Natale A., Ghio D., Tarchi D., Goujon A., et al. COVID-19 cases and case fatality rate by age. In: Knowledge for Policy. 2020: 1-18.

5. Korostovtseva L.S., Rotar O.P., Konradi A.O. COVID-19: what are the risks of hypertensive patients? Arterial’naya gipertenziya [Arterial Hypertension]. 2020; 26 (2): 124-32. (in Russian)

6. Pradhan A., Olsson P Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020; 11 (1): 1-11. DOI: https://doi.org/10.1186/s13293-020-00330-7

7. Scully E., Haverfield J., Ursin R., Tannenbaum C., Klein S. Considering how biological sex impacts immune responses and COVID-19 outcomes. J Nat Rev Immunol. 2020; 20: 1-6. DOI: https://doi.org/10.1038/s41577-020-0348-8

8. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

9. Lian J., Jin X., Hao S., et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) outside Wuhan. Clin Infect Dis. 2020; 71 (15): 740- 7. DOI: https://doi.org/10.1093/cid/ciaa242

10. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; March 26: 1-14. DOI: https://doi.org/10.1136/bmj.m1091

11. Gambaryan M.G., Drapkina O.M. Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current scientific literature. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (3): 331-8. (in Russian)

12. Mareev Yu.V., Mareev V.Yu. Role of age, comorbidity and reninan-giotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers. Kardiologiya [Cardiology]. 2020; 60 (4): 4-9. (in Russian)

13. Popkin B., Du S., Green W., et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020; 21 (11): 1-17. DOI: https://doi.org/10.1111/obr.13128

14. Dietz W., Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring). 2020; 28 (6): 1005. DOI: https://doi.org/10.1002/oby.22818

15. Cai Q., Chen F., Wang T., et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020; 43 (7): 1392-8. DOI: https://doi.org/10.2337/dc20-0576

16. Zaytsev A.A., Golukhova E.Z., Mamalyga M.L., Kryukov E.V., et al. Effectiveness of pulse methylprednisolone therapy in COVID-19 patients. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya [Clinical Microbiology and Antimicrobial Chemotherapy]. 2020; 22 (2): 88-91. DOI: https://doi.org/10.36488/cmac.2020.2.88-91 (in Russian)

17. Guan W., Ni Z., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032

18. Lawrence H., Hunter A., Murray R., Lim W., McKeever T. Cigarette smoking and the occurrence of influenza - systematic review. J Infect. 2019; 79 (5): 401-6. DOI: https://doi.org/10.1016/jjinf.2019.08.014

19. Liu W., Tao Z., Wang L., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020; 133 (9): 1032-8. DOI: https://doi.org/10.1097/CM9.0000000000000775.

20. Zhao J., Yang Y., Huang H., et al. Relationship between the ABO Blood Group and the COVID-19 susceptibility. medRxiv. 2020; March 27: 1-18. DOI: https://doi.org/10.1101/2020.03.11.20031096

21. Pourali F., Afshari M., Alizadeh-Navaei R., et al. Relationship between blood group and risk of infection and death in COVID-19: a live metaanalysis. medRxiv. 2020; June 8: 1-14. DOI: https://doi.org/10.1101/2020.06.07.20124610

22. Reid M., Mohandas N. Red blood cell blood group antigens: structure and function. Semin Hematol. 2004; 41 (2): 93-117. DOI: https://doi.org/10.1053/j.seminhematol.2004.01.001

23. Poschmann A., Fischer K., Seidl S., et al. ABH receptors and red cell survival in a «Bombay» blood: immunofluorescence studies by phytohemagglutinins and helix agglutinins. Vox Sang. 1974; 27 (4): 338-46. DOI: https://doi.org/10.1111/j.1423-0410.1974.tb02426.x

24. Tiongco R., Paragas N., Dominguez M. ABO blood group antigens may be associated with increased susceptibility to schistosomiasis: a systematic review and meta-analysis. J Helminthol. 2020; 94: е21. DOI: https://doi.org/10.1017/S0022149X18001116

25. Guillon P., Clement M., Sebille V., et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008; 18 (12): 1085-93. DOI: https://doi.org/10.1093/glycob/cwn093

26. Batool Z., Durrani S., Tariq S. Association of ABO and Rh blood group types to hepatitis B, hepatitis C, HIV and Syphillis infection, a five year’ experience in healthy blood donors in a tertiary care hospital. J Ayub Med Coll Abbottabad. 2017; 29 (1): 90-2.

27. Notari A., Torrieri G. COVID-19 transmission risk factors. medRxiv. 2020; May 7: 1-42. DOI: https://doi.org/10.1101/2020.05.08.20095083

28. Yang J., Koh H., Moon S., et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol. 2020; 146 (4): 790-8. DOI: https://doi.org/10.1016/jjaci.2020.08.008

29. Lopatin A.S., Chuchueva N.D. Epidemiology of allergic rhinitis in Russia and in the world. Rossiyskiy allergologicheskiy zhurnal [Russian Al-lergological Journal]. 2013; (2): 3-11. (in Russian)

30. Goren A., McCoy J., Wambier C., et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020; March 8: 1-2. DOI: https://doi.org/10.1111/dth.13365.

31. Wambier C., Vano-Galvan S., McCoy J., et al. Androgenetic alopecia present in the majority of hospitalized with COVID-19 patients - the «Gabrin sign». J Am Acad Dermatol. 2020; 83 (2): 680-2. DOI: https://doi.org/10.1016/j.jaad.2020.05.079

32. Wambier C., McCoy J., Goren A. Male balding as a major risk factor for severe COVID-19: a possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. J Am Acad Dermatol. 2020; 83 (6): e400-2. DOI: https://doi.org/10.1016/j.jaad.2020.09.015

33. Moradi F., Enjezab B., Ghadiri-Anari A. The role of androgens in COVID-19. Diabetes Metab Syndr Clin Res Rev. 2020; 14 (6): 2003-6. DOI: https://doi.org/10.1016/j.dsx.2020.10.014

34. Renieri A., Benetti E., Tita R., et al. ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian. medRxiv. 2020; June 2: 1-28. DOI: https://doi.org/10.1101/2020.04.03.20047977

35. Saad-Roy M., Wagner C., Baker R., et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science. 2020; 370 (6518): 811-8. DOI: https://doi.org/10.1126/science.abd7343

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»